ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > PDGF R beta

PDGF R beta

概要

Name:Platelet-derived growth factor receptor beta
Target Synonym:EC:2.7.10.1,PDGFRB,Platelet Derived Growth Factor Receptor Beta,Platelet-Derived Growth Factor Receptor, Beta Polypeptide,Beta-Type Platelet-Derived Growth Factor Receptor,PDGFR-Beta,PDGFR,Activated Tyrosine Kinase PDGFRB,CD140b Antigen,NDEL1-PDGFRB,EC 2.7.10.1,CD140B,JTK12,PENTT,IMF1,KOGS,IBGC4,Receptor, Platelet-Derived Growth Factor beta,Beta platelet-derived growth factor receptor,EC 2.7.10,CD140 antigen-like family member B,PDGFR-1,PDGF-R-beta,PDGFR1,Platelet-derived growth factor receptor
Number of Launched Drugs:11
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
PDB-C52H3 Canine Canine PDGF R beta / CD140b Protein, His Tag
PDB-C52H3-structure
PDB-C52H3-sds
PDB-H5259 Human Human PDGF R beta / CD140b Protein, Fc Tag
PDB-H5259-structure
PDB-H5259-sds
ACRO Quality

生物活性データの一部

PDB-H5259-ELISA
 PDGF R beta ELISA

Immobilized Human PDGF-BB, premium grade (Cat. No. PDB-H4112) at 1 μg/mL (100 μL/well) can bind Human PDGF R beta, Fc Tag (Cat. No. PDB-H5259) with a linear range of 0.6-10 ng/mL (QC tested).

PDB-C52H3-ELISA
 PDGF R beta ELISA

Immobilized Human PDGF-BB, premium grade (Cat. No. PDB-H4112) at 1 μg/mL (100 μL/well) can bind Canine PDGF R beta / CD140b, His Tag (Cat. No. PDB-C52H3) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name

PDGFRB,CD140B,JTK12,PDGF-R-beta,PDGFR-2,PDGFR-beta,PDGFR-¦Â

Background

Human platelet-derived growth factor receptor, beta polypeptide (PDGFRB) is also called J03278, M21616, CD140B, JTK12, PDGF-R-beta and PDGFR, is receptor that binds specifically to PDGFB and has a tyrosine-protein kinase activity. Is a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor (PDGF) family. The PDGFR/PDGF system includes two receptors (PDGFRA and PDGFRB) and four ligands (A, B, C and D). The receptors PDGFRA and PDGFRB are related in sequence and both are members of the class III subtype of receptor tyrosine kinases (RTKs). Other class III RTKs are CSF1R, KIT and FLT3. PDGF binding induces receptor homo- and heterodimerization and signal transduction. The expression of the ¦Á and ¦Â receptors is independently regulated in various cell types. Recombinant soluble PDGFRB binds PDGF with high affinity and is potent PDGF antagonist. The ligands form either homo- or heterodimers (PDGF-AA, -AB, -BB, -CC, -DD). The four PDGFs are inactive in their

相関分子

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt United States Mastocytosis, Systemic; Leukemia, Mast-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Acute Novartis Pharmaceuticals Corp 2017-04-28 Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD; SCAI-003 Approved Pfizer Pharmaceuticals Ltd (China) Sutent, 索坦 United States Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell Cppi Cv 2006-01-26 Solid tumours; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leiomyosarcoma; Fibrosarcoma; Leukemia; Kidney Neoplasms; Teratoma; Head and Neck Neoplasms; HIV Infections; Intestinal Neoplasms; Ovarian Neoplasms; Ependymoma; Leukemia, Myeloid, Accelerated Phase; Fibromatosis, Aggressive; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; Leukemia, Myelogenous, Chronic; Carcinoma, Renal Cell; Pheochromocytoma; Histiocytoma, Malignant Fibrous; Thoracic Neoplasms; Hemangioblastoma; Leukemia, Hairy Cell; Abdominal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Polycythemia Vera; Esophageal Neoplasms; Carcinoma; Pelvic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Glioblastoma; Myelodysplastic Syndromes; Carcinoma, Papillary; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Neurofibromatoses; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Adenoma, Islet Cell; Myeloproliferative Disorders; Pancreatic Neoplasms; Plasmacytoma; Carcinoma, Transitional Cell; Immunogl Details
Dasatinib Hydrate BMS-354825; XS-004; NSC-732517 Approved Bristol-Myers Squibb Company Dasynoc, Spricel, Sprycel, Spraysel, 施达赛 United States Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma Bristol-Myers Squibb Company 2006-06-28 Gliosarcoma; Intraocular Lymphoma; Neoplasms, Gonadal Tissue; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lymphoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Primary Myelofibrosis; Astrocytoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Chronic-Phase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neurofibrosarcoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Sarcoma; Cholangiocarcinoma; Sarcoma, Ewing; Prostatic Neoplasms; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Mastocytosis; Mycosis Fungoides; Tongue Neoplasms; Melanoma; Heart Arrest; Neoplasm Metastasis; Brain Neoplasms; Lymphoma, T-Cell, Cutaneous; Burkitt Lymphoma; Hemangiopericytoma; Uterine Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; S Details
Becaplermin biosimilar (Virchow Group) Approved Virchow Group Healace, Plermin gel Diabetic Foot Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Carcinoma, Non-Small-Cell Lung Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Glioma; Bile Duct Diseases; Peritoneal Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Fallopian Tube Neoplasms; Nasopharyngeal Carcinoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Osteoma; Melanoma; Neoplasms; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Leiomyosarcoma; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Lung Diseases, Interstitial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC) Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef United States Idiopathic Pulmonary Fibrosis Boehringer Ingelheim Gmbh 2014-10-15 Carcinoma, Squamous Cell; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Peritoneal Neoplasms; Astrocytoma; Genital Neoplasms, Female; Hepatic Insufficiency; Silicosis; Gliosarcoma; Breast Neoplasms; Lung Neoplasms; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Adenocarcinoma; Glioblastoma; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoma, Renal Cell; Carcinoid Tumor; Endometrial Stromal Tumors; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Ovarian Neoplasms; Scleroderma, Systemic; Neoplasms; Small Cell Lung Carcinoma; Lung Diseases, Interstitial; Mesothelioma; Pulmonary Fibrosis; Multiple Myeloma; Asbestosis; Oligodendroglioma; Neuroendocrine Tumors Details
Ripretinib DCC-2618 Approved Deciphera Qinlock, 擎乐 United States Gastrointestinal Stromal Tumors Deciphera Pharmaceuticals Llc 2020-05-15 Neoplasms; Mastocytosis, Systemic; Gastrointestinal Stromal Tumors Details
Becaplermin RWJ-60235; rhPDGF-BB (Janssen) Approved Regranex United States Ulcer; Lower extremity diabetic neuropathic ulcers Smith & Nephew Healthcare Ltd 1997-12-16 Diabetic Foot; Diabetic Neuropathies; Lower extremity diabetic neuropathic ulcers; Skin Ulcer; Foot Ulcer; Parkinson Disease; Ulcer; Varicose Ulcer Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Colorectal Neoplasms Bayer Healthcare Pharmaceuticals Inc 2012-09-27 Esophageal adenocarcinoma; Osteosarcoma; Sarcoma, Ewing; Bile Duct Neoplasms; Peritoneal Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Fallopian Tube Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Sarcoma; Leukemia, Myeloid, Acute; Thymoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Somatostatinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Solid tumours; Liver Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Insulinoma; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Glucagonoma; Carcinoma, Adenoid Cystic; Adenoma; Gastrinoma Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma United States Carcinoma, Renal Cell; Sarcoma Novartis Pharma Ag 2009-10-19 Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc Nexavar, 多吉美 United States Carcinoma, Renal Cell Bayer Healthcare Pharmaceuticals Inc 2005-12-01 Liver Neoplasms; Leiomyosarcoma; Solid tumours; Recurrence; Ovarian Neoplasms; Leukemia, Erythroblastic, Acute; Rhabdomyosarcoma; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Fibromatosis, Aggressive; Kidney Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangiosarcoma; Carcinoid Tumor; Stomach Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Islet Cell; Esophageal Neoplasms; Rectal Neoplasms; Vipoma; Myelodysplastic Syndromes; Neoplasms; Wilms Tumor; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Small Cell Lung Carcinoma; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Multiple Endocrine Neoplasia Type 2a; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Leukemia, Myelomonocytic, Ch Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
18F-Dasatinib 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma Details
Metarafenib Phase 1 Clinical Guangzhou Nanxin Pharma Co Ltd Liver Neoplasms; Solid tumours Details
Telatinib EOC-315; BAY-57-9352 Phase 2 Clinical Bayer AG Solid tumours; Stomach Neoplasms Details
Crenolanib Besylate CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma Details
Tafetinib Malate SIM-0702; SIM-1005; SIM-010603 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd Neoplasms Details
Axitinib injectable suspension (Clearside Biomedical) CLS-1002; CLS-011-A; CLS011A; CLS-AX Phase 2 Clinical Clearside Biomedical Inc Macular Degeneration Details
Lucitanib S-80881; AL-3810; CO-3810; E-3810; S-80881-2 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Nintedanib Solution for Inhalation AP02; AP-02 Phase 1 Clinical Avalyn Pharma Inc Idiopathic Pulmonary Fibrosis Details
ZSP-1603 ZSP-1603 Phase 2 Clinical Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
KDR2-2 Phase 2 Clinical Guangzhou Huiborui Biomedical Technology Co Ltd Neovascularization, Pathologic; Glaucoma, Neovascular; Corneal Neovascularization Details
Sorafenib/MG-005 MG-D-1509; MGD-1509 Tri-Service General Hospital, Metagone Biotech Inc Details
Sorafenib Tosylate/Comekibart MG-D-1609 Phase 2 Clinical Metagone Biotech Inc Solid tumours Details

This web search service is supported by Google Inc.

totopphone